Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015, and currently has eight commercialized biosimilars in a number of markets with over 20 assets in its pipeline. Biosimilars now account for 31% of net sales, reflecting the company's strategic pivot.
Cyborg Score Rationale
Sandoz demonstrates strong fundamentals with $10.6B revenue, $32B market cap, and leadership in both generics and biosimilars. Growing biosimilar segment (31% of sales) and robust pipeline provide growth momentum. However, pricing pressures and regulatory headwinds present ongoing challenges.
Top Insights
Biosimilars now represent 31% of net sales, demonstrating successful strategic pivot from pure generics manufacturer
Post-IPO (October 2023), company projects revenue growth from $10.6B (2024) to $11.9B (2026) despite 3% price erosion
Complex injectable generics and biosimilar leadership provide differentiation in commoditized generic pharma sector
20,000 employees and presence across 130+ countries supports scale advantages in manufacturing and distribution
Named Competitors
Generics Portfolio — Leading generic pharmaceutical manufacturer
Biosimilars — Growing biosimilar and generic player
Specialty Generics — Injectable and specialty generics focus
Biosimilar Portfolio — Established biosimilar innovator
Recent Developments
(October 2025) Biosimilars growth acceleration with multiple new launches including denosumab and natalizumab biosimilars in key markets
(February 2026) Next earnings date February 25, 2026 with FY2025 EPS guidance of $3.31 and FY2026 guidance of $3.89
(2024-2025) Strategic acquisitions including Cimerli (biosimilar, $170M) to expand ophthalmology portfolio and just-evotec biologics partnership
Open the full interactive Sandoz Group AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.